The Significance of JTCC Joining Georgetown Lombardi Cancer Consortium | OncLive

The Significance of JTCC Joining Georgetown Lombardi Cancer Consortium

May 17, 2019

Robert C. Garrett, FACHE, chief executive officer, Hackensack Meridian Health, discusses the significance of John Theurer Cancer Center joining the Georgetown Lombardi Cancer Consortium.

Robert C. Garrett, FACHE, chief executive officer, Hackensack Meridian Health, discusses the significance of John Theurer Cancer Center (JTCC) joining the Georgetown Lombardi Cancer Consortium.

In May 2019, JTCC was approved to become a member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center Consortium. Joining the consortium puts JTCC in an elite group, as only 16 cancer centers are part of this designation, Garrett says. This will allow JTCC to compete more effectively with the well-known institutions in New York and Philadelphia that are geographically close by. More research dollars will be coming into the institution, allowing patients to be exposed to more clinical trials. JTCC will truly be a comprehensive cancer center, Garrett adds.

He concludes that this consortium will not only rank JTCC among the best cancer centers in the region, but it will also bring more hope for patients with cancer that are treated at JTCC.


x